Bio-Techne misses, sees flat Q4 organic revenue before FY27 re-acceleration

 

Bio-Techne misses fiscal Q3 estimates with EPS $0.53 and revenue $311.4M, sees flat Q4 organic revenue before FY27 re-acceleration

• GAAP EPS $0.32, alongside adjusted EPS $0.53 reported for fiscal Q3 2026
• Investor takeaway: Reported organic revenue -2%, but +2% excluding cell therapy and OEM timing.
• Investor takeaway: Large pharma, spatial biology, GMP proteins strong; emerging biotech weakness fully explains shortfall.
• Investor takeaway: Biggest positive was 310 bps sequential adjusted operating margin expansion to 34.2%.
• Investor takeaway: Key risk is timing and magnitude of emerging biotech recovery into fiscal 2027.
• Key results: Q3 revenue $311.4M (-2% YoY), adjusted EPS $0.53 (down $0.03 YoY).
• Guidance: Q4 organic revenue about flat; ex-cell-therapy headwind, low single-digit underlying growth expected.
• Growth drivers: Large pharma double-digit growth; COMET spatial >65%; GMP proteins ~+50% ex-two fast-track customers.
• Problem areas: Emerging biotech revenue -high single digits; core reagents -mid-single digits before timing adjustment.
• Margins: Adjusted gross margin 70.4% (down 120 bps YoY), operating margin 34.2% (down 70 bps YoY).
• Management tone: Cautious near term but clearly optimistic about mid-single-digit-plus growth potential in fiscal 2027.
• Main concern: Prolonged softness and unpredictable inflection timing in emerging biotech spending despite strong recent funding.
• Mixed quarter, driven by strong pharma and high-growth platforms offset by weaker emerging biotech demand.
• Company declared a cash dividend in conjunction with its fiscal Q3 2026 results

https://finviz.com/quote?t=TECH&p=d